Hybio Pharmaceutical Co. Hits Day Low at CNY 22.14 Amid Price Pressure

Hybio Pharmaceutical Co. experienced a notable decline today, with the stock falling by 3.98% on June 1, 2026. The stock reached an intraday low of CNY 22.14, reflecting a challenging trading session. Despite this downturn, Hybio has shown strong performance metrics over the past year, boasting a remarkable 55.28% increase compared to the China Shanghai Composite's 21.22% gain. In the short term, Hybio's performance has been mixed, with a 12.67% drop over the past week, contrasting sharply with its 6.99% rise over the past month. Year-to-date, the stock remains up by 23.97%, indicating resilience in a fluctuating market. The company has reported impressive growth in operating profit, with a 179.39% increase, and has maintained positive results for seven consecutive quarters. Additionally, Hybio's operating cash flow reached a high of CNY 267.19 million, and raw material costs have decreased by 25.74% year-over-year. However, the stock's valuation presents some risks, as indicated by a return on equity of -11.50% and a price-to-book ratio of 24.07.